HK Stock MarketDetailed Quotes

LUYE PHARMA (02186)

Watchlist
  • 2.810
  • +0.010+0.36%
Trading Apr 13 10:42 CST
11.22BMarket Cap16.34P/E (TTM)

LUYE PHARMA (02186) Revenue Breakdown Overview

By Business/Source

Currency:CNY
2025/FY
Stock NameRevenueRatio
Tumor drugs2.3B36.42%
Central nervous system drugs2.03B32.15%
Cardiovascular system drugs1.15B18.27%
Other482.05M7.64%
Digestive and metabolic drugs348.76M5.53%

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
Tumor drugs2.3B36.42%
Central nervous system drugs2.03B32.15%
Cardiovascular system drugs1.15B18.27%
Other482.05M7.64%
Digestive and metabolic drugs348.76M5.53%

By Country/Region

Currency:CNY
2025/FY
Stock NameRevenueRatio
The mainland of China5.14B81.41%
EU538.99M8.54%
亚洲(中国内地除外)499.1M7.91%
Other countries134.49M2.13%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More